Details

Last Funding Type

Series Unknown

Last Funding Money Raised

$15M

Industries

Biotechnology,Health Care,Medical,Therapeutics

Founded date

Jan 1, 2018

Number Of Employee

101 - 250

Operating Status

Active

Legal Name

Neogene Therapeutics, Inc.

Neogene Therapeutics provides cancer patients with T cell therapies targeting mutated proteins called neo-antigens. The company is developing novel technologies to enable the engineering of ‘designer T cells’ with neo-antigen specificities that display an optimized ability to seek and destroy cancer cells.

Neogene's platform allows for the isolation of neo-antigen specific TCR genes from tumor biopsies that are routinely obtained from cancer patients during treatment. The tumor-infiltrating lymphocytes (TIL) obtained by these tumor biopsies frequently express TCRs specific for mutated proteins found in cancer cells (neo-antigens). The company’s proprietary technology uses state-of-the-art DNA sequencing, DNA synthesis and genetic screening tools to identify such neo-antigen specific T cell receptor genes within tumor biopsies with high sensitivity, specificity and at scale.